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Rationale: Obesity may contribute to the development and clinical expression of asthma.
However, how obesity can influence response to asthma medications is still uncertain.
Objectives: To examine the relationship between body mass index (BMI) and the response
to an inhaled corticosteroid (ICS), fluticasone propionate, with or without the long-acting
b2-agonist salmeterol (LABA).
Methods: Achievement of asthma control as defined by the global initiative on asthma
guidelines (GINA) was examined in 1242 asthmatic patients not currently using ICS,
enrolled in five clinical trials comparing fluticasone propionate and the combination of
fluticasone and salmeterol.
Results: In both obese and non-obese subjects, fluticasone propionate combined with
salmeterol was more effective in controlling asthma than fluticasone alone. However, for
both treatments the odds of achieving well-controlled asthma were significantly lower in
obese subjects, particularly among those with a BMI ofX40 kg/m2. Reported prevalence of
atopy increased with BMI. Age did not influence the effect of obesity in response to asthma
medications.
Conclusion: Obese patients are less likely than the non-obese to achieve asthma control
with an ICS or an ICS combined with a LABA. The causes of such reduced response to
asthma medication in obese subjects should be studied, and their implications for asthma
therapy determined.
& 2007 Published by Elsevier Ltd.Published by Elsevier Ltd.
6 4747; fax: +418 656 4762.
al.caIntroduction
Obesity and asthma have been rapidly increasing in
prevalence,1,2 and there is evidence suggesting that obesity
may contribute to the development of asthma.3,4 Moreover,
the association between obesity and asthma seems more
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Obesity and asthma therapy 2241evident in women than men.5–7 Among the mechanisms
proposed to explain a potential causal relationship are the
influence of weight on lung mechanics, changes in the
immune or inflammatory responses, and factors related
either to common genetic determinants or lung develop-
ment.8–10 Obesity may also influence the severity of pre-
established asthma and its clinical expression, and reduc-
tions in body weight have been universally associated with
an improvement in asthma outcomes.11–14
According to current guidelines, inhaled corticosteroids
(ICS) are the mainstay of asthma treatment. However when
asthma control is not achieved by low ICS doses, inhaled
long-acting b2-agonists (LABA) or other medications may be
used as add-on therapy.15,16 Two recent publications suggest
that asthma is more difficult to control in overweight
asthmatics patients and that body mass index (BMI)
modulates response to asthma therapy, particularly ICS.
One of these studies reported that overweight patients had
a smaller likelihood of transitioning from an unacceptable to
an acceptable health state.17
However there have been few studies examining this
modulation of response to therapy. The present analysis
followed on these preliminary results by examining through
a pooled analysis of studies the influence of an ICS,
fluticasone propionate alone or in combination with salme-
terol on asthma control in obese and non-obese, non-
smoking patients not using ICS for at least 3 months prior to
visit 1 of the clinical trial.Methods
Study design
We analyzed pooled data obtained from recent studies
comparing the effects on asthma control in moderately
asthmatic subjects on fluticasone (100 mg) bid to a combina-
tion of fluticasone+salmeterol (50/100 mg) bid. All studies
had a run-in period of 2–4 weeks during which patients were
using a short-acting b2-agonist (SABA) alone followed by a
12-week period of treatment with fluticasone or fluticaso-
ne+salmeterol. Each of these trials had a multicenter,
double-blind, randomized, parallel-group study design.
Furthermore, all had similar inclusion and exclusion criteria
and used the same fluticasone and fluticasone+salmeterol
dosing for the first 12 weeks of treatment. ICS should not
have been used for at least 1 month before the study (six for
the GOAL study). Patients with recent exacerbations
requiring ER visit within the last 4–6 weeks or hospitalization
within 12 weeks prior to visit 1 were also excluded.
Baseline information on age, gender, smoking habits
(former or never), race, BMI, duration of asthma and
presence or absence of atopy was collected after the run-
in period but before randomization. Subjects had the
following parameters assessed weekly and recorded in their
daily record cards during the 12 weeks of treatment: daily
symptom scores, night-time awakening, asthma exacerba-
tions, use of relief medication (SABA), visits to an
emergency room, and percent predicted morning peak
expiratory flow (PEF).
The primary composite outcome for the aggregated
clinical trials was asthma control. The main objective ofthis study was to assess the effect of obesity on asthma
control. The intent-to-treat population data for these trials
was used in the analysis. Protocols were accepted by the
local institutional Ethics Committees and all patients
included signed an informed consent form.
Inclusion criteria
The aggregated patients included from the trials in this
analysis were steroid-naı¨ve, not currently smoking, former
smokers stopped smoking at least 4 weeks prior (to the
screening visit), and had uncontrolled asthma using a SABA
alone. All patients had one or more of the following
characteristics: a documented clinical history of asthma as
defined by the American Thoracic Society; a 15% improve-
ment in forced expiratory volume in one second (FEV1) when
measured pre- and post-inhalation of a SABA in the 6 months
before study entry; a 15% increase in FEV1 following
administration of 200–400 mg of inhaled salbutamol at study
entry or at the pre-randomization visit.19 To be included,
patients also had to have X5 days of data from the run-in
period, and have not used corticosteroids for X1 month
before entry into the clinical trial.
Other inclusion criteria were: age 18 and over and a
baseline predicted FEV1X60% (Table 1). All subjects had
symptomatic, persistent asthma that was uncontrolled
according to global initiative for asthma (GINA) guidelines.16
Furthermore, over the last 7 consecutive days of run-in the
patients had to have one or more of the following: an
asthma symptom score of X2 on at least 3 days; disruptions
of normal sleep patterns on two or more occasions; or,
required rescue bronchodilator medication on X4 days. All
patients used an inhaled SABA as a rescue medication.
Evaluation
Asthma symptoms and expiratory flow data were used to
determine the proportion of patients who achieve asthma
control at 12 weeks.16
Assessment of asthma control
‘‘Well-controlled’’ asthma was defined as meeting two or
more of the following criteria: (1) symptoms on no more
than 2 days with a symptom score of41; (2) no more than 2
days of rescue salbutamol (SABA) use, up to a maximum of
four occasions (eight inhalations) per week; 3) X80%
predicted a.m. PEF every day, and all of the following
criteria: (a) no night-time wakening due to asthma; (b) no
emergency visits; (c) no exacerbations; and (d) no treat-
ment-related adverse effects enforcing a change in asthma
therapy. For a week to be evaluable, all individual criteria
for that week had to have been evaluable. However, if PEF,
symptom score or rescue salbutamol use was unevaluable, it
was assumed that the criterion was not ‘well controlled.’
Subjects were allowed to fail one of these three criteria and
still be classified as ‘well controlled.’
If a subject had o7 days of data available within a
specific week, but had clearly failed the criteria required to
achieve control, asthma was classified as ‘not controlled’ for
that week. A patient was classified as ‘controlled’ if all
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Table 1 Baseline demographics (N ¼ 1242).
Study id N (%)
GOAL 641 (51.6)
PACE 372 (30.0)
SAS30001 107 (8.6)
SAS30003 37 (3.0)
SAS30017 85 (6.8)
Age (y): mean 38, range 18–82
18–35 579 (46.6)
36–50 421 (33.9)
51–65 203 (16.3)
65+ 39 (3.1)
Gender
Female/male 775 (62.4)/467 (37.6)
Duration of asthma
o5 y 325 (26.2)
5 to o10 y 200 (16.1)
410 y 717 (57.7)
Atopy
Yes/no 856 (68.9)/313 (25.2)
Unknown 73 (5.9)
Smoking
Former/never 292 (23.5)/950 (76.5)
Race
White 985 (79.3)
Asian 152 (12.2)
Other 105 (8.5)
BMI
Underweight 78 (6.3)
Normal weight 454 (36.6)
Overweight 394 (31.7)
Obese class I 182 (14.7)
Obese class II 76 (6.1)
Obese class III 58 (4.7)
L.-P. Boulet, E. Franssen2242control criteria were obtained for at least 5 out of 7 days. If
o5 days of data had been provided for the week, asthma
was classified as ‘unevaluable,’ regardless of whether
criteria for control were met for those days. Each exacer-
bation was characterized by the investigator as mild,
moderate or severe based on the following definitions:
Mild Morning PEF420% below baseline (mean of last 7 days of
run-in period) for X2 consecutive days, OR. Use of additional rescue medication on more than three
occasions/24 h period (with respect to baseline) for X2
consecutive days, OR. Awakening at night due to asthma for X2 consecutive
nights.
Moderate Morning PEF430% below baseline (mean of last 7 days of
run-in) for X2 consecutive days OR. The investigator’s opinion. Deterioration in asthma requiring emergency hospital
Severetreatment or hospital admission OR.
 The investigator’s opinion.
We also wanted to evaluate the effect obesity on FEV1;
unfortunately more than half of the patients in obesity
classes II and III came from a study not measuring FEV1 at the
end of the 12 weeks treatment and the effect of obesity in
this parameter could not be studied.
Baseline data for each parameter was averaged for each
patient for the last 7 consecutive days of the run-in period of
the study (Table 2).
BMI was derived without adjustment for age or gender,
and classified as underweight (BMI o20 kg/m2), normal
weight (BMI 20–o25 kg/m2), overweight (BMI 25–o30kg/m2),
obesity class I (BMI 30–o35 kg/m2), obesity class II (BMI
35–o 40 kg/m2) and obesity class III (BMI X40 kg/m2).
Atopy was considered to be present if there was a positive
answer to a history of atopy, seasonal rhinitis or eczema, or
when there was evidence in the medical chart of a raised
serum IgE, blood eosinophilia or positive allergy skin tests.Statistical analysis
Asthma control was the main outcome in each of the five
trials used for this pooled analysis, and was calculated in
each trial using the same algorithm. Continuous variables
were summarized using means, minimum, and maximum;
categorical variables using frequency count and percen-
tages. Logistic regression was used to analyze the effect of
BMI on asthma control.
Primary analysis was to determine the effect of BMI using
the six categories defined earlier adjusting for covariates.
Covariates included study protocol, sex, age, smoking
status, treatment assigned (at random), atopy and asthma
duration. Models were run with and without interactions of
covariates with BMI. Also, single variable logistic regressions
for all covariates minus study protocol were done. Main
effects were declared statistically significant at pp0.05 and
interactions at pp0.1.
Statistical assessment of the relationship of gender and
BMI to asthma control was not possible in this analysis, as
most of the male patients had either normal weight or were
overweight.
We used the three categories of obese patients as
currently suggested in current guidelines, for subjects with
a BMI greater than 30, as the various degrees of obesity
could have a different response to therapy.Results
The five studies included 2041 steroid-naı¨ve, currently non-
smoking patients.20–24 Seven hundred ninety-nine of these
patients were excluded, leaving 1242 patients whose data
were analyzed in the present study. The main reasons for
exclusion were age under 18, current smoking, BMI unavail-
able, FEV1o60% or missing from the database and insuffi-
cient data to evaluate symptom control at week 12.
ARTICLE IN PRESS
Table 2 Clinical parameters and pulmonary function (N ¼ 1242).
Under weight Normal weight Over weight Obese class I Obese class II Obese class III Total
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Daily symptoms (24 h)
Yes 50 (64.1) 311 (68.5) 298 (75.6) 134 (73.6) 61 (80.3) 48 (82.8) 902 (72.6)
No 28 (35.9) 139 (30.6) 94 (23.9) 44 (24.2) 14 (18.4) 10 (17.2) 329 (26.5)
Missing 0 4 (0.9) 2 (0.5) 4 (2.2) 1 (1.3) 0 11 (0.9)
Daily rescue use
Yes 35 (44.9) 228 (50.2) 234 (59.4) 97 (53.3) 42 (55.3) 34 (58.6) 670 (53.9)
No 43 (55.1) 223 (49.1) 155 (39.3) 80 (44.0) 31 (40.8) 24 (41.4) 556 (44.8)
Missing 0 3 (0.7) 5 (1.3) 5 (2.8) 3 (4.0) 0 16 (1.3)
Mean rescue use Xtwo doses per day
Yes 24 (30.8) 148 (32.6) 171 (43.4) 75 (41.2) 29 (38.2) 25 (43.1) 472 (38.0)
No 54 (69.2) 303 (66.7) 218 (55.3) 102 (56.0) 44 (57.9) 33 (56.9) 754 (60.7)
Missing 0 3 (0.7) 5 (1.3) 5 (2.8) 3 (4.0) 0 16 (1.3)
Awakening 1 or more nights
Yes 43 (55.1) 269 (59.3) 217 (55.1) 95 (52.2) 34 (44.8) 28 (48.3) 686 (55.2)
No 34 (43.6) 180 (39.7) 162 (41.1) 81 (44.5) 40 (52.6) 29 (50.0) 526 (42.4)
Missing 1 (1.3) 5 (1.1) 15 (3.8) 6 (3.3) 2 (2.6) 1 (1.7) 30 (2.4)
Awakening 2 or more nights
Yes 35 (44.9) 206 (45.4) 169 (42.9) 74 (40.7) 26 (34.2) 24 (41.4) 534 (43.0)
No 42 (53.9) 243 (53.5) 210 (53.3) 102 (56.0) 48 (63.2) 33 (56.9) 678 (54.6)
Missing 1 (1.3) 5 (1.1) 15 (3.8) 6 (3.3) 2 (2.6) 1 (1.7) 30 (2.4)
% Predicted PEF (a.m.)
o60% 9 (11.5) 39 (8.6) 35 (8.9) 10 (5.5) 3 (4.0) 3 (5.2) 99 (8.0)
60% to o80% 42 (53.9) 205 (45.2) 142 (36.0) 62 (34.0) 26 (34.2) 25 (43.1) 502 (40.4)
X80% 27 (34.6) 207 (45.6) 214 (54.3) 105 (57.7) 46 (60.5) 30 (51.7) 629 (50.6)
Missing 0 3 (0.7) 3 (0.8) 5 (2.8) 1 (1.3) 0 12 (1.0)
% Reversibility
o20% 27 (34.6) 216 (47.6) 184 (46.7) 101 (55.5) 51 (67.1) 39 (67.2) 618 (49.8)
X20% 32 (41.0) 166 (36.6) 160 (40.6) 69 (37.9) 18 (23.7) 15 (25.9) 460 (37.0)
Missing 19 (24.4) 72 (15.9) 50 (12.7) 12 (6.6) 7 (9.2) 4 (6.9) 164 (13.2)
% Predicted FEV
60% to o80% 35 (44.9) 186 (41.0) 153 (38.8) 78 (42.9) 28 (36.8) 18 (31.0) 498 (40.1)
X80% 43 (55.1) 268 (59.0) 241 (61.2) 104 (57.1) 48 (63.2) 40 (69.0) 744 (59.9)
Obesity and asthma therapy 2243Patient characteristics
Six hundred and forty-one of the 1242 patients (51.6%) were
from the gaining optimal asthma control (GOAL) study (20),
372 were (30%) from the program of Advair control and
effectiveness (PACE) study,21 107 (8.6%) from the SAS30001
trial, 37 (3%) from the SAS30003 study and 85 (6.8%)
from SAS30017.24 The last three trials used metered dose
inhaler (MDI)-42 and 88mcg are the ex-actuator doses of
salmeterol and fluticasone, respectively, which are equiva-
lent to the ex-valve doses of 50 and 100mcg used in the first
two trials.
Patient’s characteristics are detailed on Table 1 and their
distribution according to BMI and gender are shown in
Figure 1. A large number of patients were either overweight
or obese, at 31.7% and 25.5%, respectively. Notably, the
study population included nearly twice as many women than
men. Furthermore, approximately one-quarter of thepatients were ex-smokers and the majority reported a
history of atopy.
The mean percent predicted PEF was 81% (range 32–182%)
and the mean FEV1 was 83% (range 60–148%) on entry in the
study. Mean bronchodilator response was 20% (range 21 to
+96%).
The percentage of patients with atopy increased with
rising BMI: 63% of patients who were underweight had atopy,
as did 74% of those with normal weight, 72% of those
who were overweight: 73% in obesity class I, 77% of those
in obesity class II and 82% in obesity class III. Furthermore,
the weight distribution was different in both genders
(Figure 1).
A breakdown by BMI category of the clinical parameters of
asthma control and pulmonary function is summarized in
Table 2. As expected for patients with uncontrolled asthma,
the majority had diurnal and/or nocturnal asthma symp-
toms, and more than half used daily rescue bronchodilators.
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Table 3 Control status according to weight classification (N ¼ 1242).
Fluticasone alone Salmeterol and Fluticasone N
Controlled Uncontrolled Controlled Uncontrolled
N (%) N (%) N (%) N (%)
Underweight 25 (8.3) 18 (5.7) 24 (6.0) 11 (4.9) 78
Normal weight 120 (39.7) 108 (34.0) 152 (38.2) 74 (33.0) 454
Overweight 87 (28.8) 103 (32.4) 133 (33.4) 71 (31.7) 394
Obese Class I 42 (13.9) 49 (15.4) 54 (13.6) 37 (16.5) 182
Obese Class II 18 (6.0) 17 (5.3) 24 (6.0) 17 (7.6) 76
Obese Class III 10 (3.3) 23 (7.2) 11 (2.8) 14 (6.3) 58
0%
10%
20%
30%
40%
50%
Female Male Pop weight
Under 
(<20)
Normal 
(20-25)
Over 
(25-30)
Obese I 
(30-35)
Obese II 
(35-40)
Obese III 
(>40)
Figure 1 Distribution of patients according to BMI.
L.-P. Boulet, E. Franssen2244An increase of daily symptoms over 24 h and % reversibility
was reported in the obese groups (Table 3).
Control of asthma according to medications
Overall, 56.4% of patients (700/1242) achieved well-
controlled asthma. This included 48.7% of those taking
fluticasone alone (302/620) and 64.0% of those on flutica-
sone+salmeterol (398/622).
Influence of BMI on asthma medication response
Figure 2 summarizes the proportion of each weight group
that achieved asthma control, while break these data down
further, by treatment type. More patients receiving flutica-
sone+salmeterol achieved asthma control than did those
receiving fluticasone alone in each BMI category (Figure 2).
However, overall fewer obese subjects achieved asthma
control than did non-obese individuals.
Treatment received, duration of asthma and BMI were
statistically significant from the logistic regression on single
variables. Only odds ratios from the adjusted model are
reported. Adjusted logistic regression demonstrated an odds
ratio of achieving well-controlled asthma with fluticasone+salmeterol compared to fluticasone alone of 1.98 (95% CI
1.56, 2.53). Furthermore, it revealed an odds ratio of
achieving well-controlled asthma in underweight subjects
compared to those in obesity class III of 3.23 (95% CI 1.50,
6.97), of 2.66 (95% CI 1.45, 4.87) in normal weight patients,
2.11 (95% CI 1.15, 3.87) in the overweight, 1.91 (95% CI1.01,
3.61) in members of obesity class I, and 2.46 (95% CI 1.17,
5.18) in members of obesity class II. Ever having smoked also
had a significant relationship with achieving asthma control
in the multivariate regression analysis (odds ratio 0.72 (95%
CI 0.54, 0.97), as did having asthma for o10 years (odds
ratio1.32 (95% CI 1.03, 1.69) (Figure 3).Interaction of covariates
From an analysis of the interactions between covariates and
BMI, only atopy was significant (p ¼ 0.022). Among patients
without atopy, there were no differences in achievement of
asthma control between each of the BMI categories.
However, in patients with atopy, there was a linear decrease
in the relative rate of asthma control with increased BMI.
The rate of asthma control among those in the underweight
category was 4.42 (95% CI 1.89, 11.05) times greater than
for those in obesity class III, while it was 2.23 (95% CI 0.99,
ARTICLE IN PRESS
0
20
40
60
80
100
SFC FP All patients
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Figure 2 Percentage of patients achieving control at 12 weeks according to BMI group.
3              5             71
BMI (vs obese class III) Odds ratio (95% CI)
Underweight 3.23 (1.50, 6.97)
Normal 2.66 (1.45, 4.87)
Overweight 2.11 (1.15, 3.87)
Obese class I 1.91 (1.01, 3.61)
Obese class II 2.46 (1.17. 5.18)
SFC vs FP 1.98 (1.56, 2.53)
Female vs male 1.17 (0.91, 1.51) ns 
Never smoke vs former 1.38 (1.03, 1.85)
Atopy (yes vs no) 1.22 (0.91, 1.63) ns 
<10 yrs asthma vs 10+ 1.32 (1.03, 1.69)
Age 1.00 (0.99, 1.01) ns 
Figure 3 Adjusted odds ratio of achieving asthma control.
Obesity and asthma therapy 22455.04) times greater for those in obesity class II than for those
in obesity class III.Discussion
This study demonstrates that people suffering from
obesity are less likely than those who are not obese to
achieve asthma control with two of the most frequently
prescribed controller medications, ICS and the combina-
tion of ICS+LABA. Morbidly obese patients are the least likely
of all to achieve asthma control. These findings are
congruent with other studies that have shown a reduced
potential for improvement of asthma symptoms in obese
subjects.17,18 However, the cause for this relationship
remains unclear and must now be elucidated by further
research.
A placebo arm was not included in the studies analyzed as
they only aimed at comparing fluticasone and the combina-tion of fluticasone and salmeterol as they were assessing the
comparative efficacy of those treatments.
Our study is in keeping with the observation of a
decreased response to corticosteroids in obese asthmatic
patients as reported by Peters-Golden et al.18 In this last
study, response to leukotriene antagonists was less affected
by BMI but this needs to be further explored. However we
showed that the reduced response to ICS, which was also
showed with combination therapy of ICS and LABA was
mostly observed in the presence of very high BMI.
Our analysis included a large group of patients that had a
relatively homogeneous degree of asthma severity. The
studies had similar designs and used the same control
criteria, as well as the same medications at equivalent
dosages. Moreover, we have no reason to believe that
compliance to therapy is different in obese subjects, and in
these studies, the compliance was high. Furthermore, one
strength of the study is the need for patients to respond to
specific diagnostic criteria for asthma at entry, so that a lack
ARTICLE IN PRESS
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wrong diagnosis. It is however possible that the lack of
control detected in this study could be related to obesity-
related symptoms and not necessarily asthma although this
is difficult to distinguish. The relationships between asthma
and obesity are complex and the role of perception of
symptoms is important in such study. Increased BMI may
indeed be associated with a reduction in FEV1, FVC,
Functional Residual Capacity and Expiratory Reserve Vo-
lume. It has been proposed that breathing at lower lung
volume could lead to a reduction in airway caliber and
consequently increase airway resistance and responsive-
ness.25,26 In this regard obesity has been associated with
increases in airway responsiveness in animal models,
although this is more controversial in humans.27,28
Other investigators have also suggested that symptoms
present in obese individuals that are interpreted as being
those of asthma may, in fact, be a discrete set of symptoms
that is linked to the obesity itself and to other pathological
physiological processes promoted by obesity.25,29 Schachter
et al.28 conducted a cross-sectional epidemiologic study in
1971 Australian adults that revealed obesity is a significant
risk factor for diagnosis of asthma, wheeze, and asthma
medication use, but not for airway hyperresponsiveness,
atopy or airflow obstruction. Furthermore, Sin et al.30
examined data from the Third National Health and Nutrition
Examination Survey and found that the most obese
participants (BMI 431 kg/m2) had the greatest risk of self-
reported asthma, dyspnea and bronchodilator us. However,
paradoxically, these patients also had the lowest risk for
airway obstruction. Since asthma is associated with a
variable, mostly TH2-type inflammatory process,5,31 while
obesity is considered to be a pro-inflammatory condition, it
is possible that the increased difficulty in obtaining disease
control in the obese is due to a more marked, or different
type of, airway inflammatory reaction.5,32,33 Genetic de-
terminants of obesity in asthmatic patients also could
influence responses to LABA or ICS.8 In addition, the
increased prevalence of co-morbidities such as gastro-
esophageal reflux reported in obese subjects29 could
influence the manifestations of asthma.
Thus perhaps the most logical conclusion from the
evidence that has accumulated to date is that asthma is
over-diagnosed and/or inappropriately treated in the obese
population, as Sin et al.30 deduce, or that obesity modulates
the clinical expression of asthma. Weight loss has been
associated with marked improvement of asthma suggesting
that some respiratory symptoms could be due to obesity or
to their influence on the physiopathology of asthma.11,12,14
This may explain the present study’s finding of reduced
asthma control in obese subjects compared to the
non-obese. However other explanations have yet to be
ruled out.
Another confounding factor that must be taken into
account in future studies is the effect of atopy on the BMI-
asthma control equation. The prevalence of atopy has been
found in many previous studies to increase significantly with
increasing quartiles of BMI.34,35 In the present study we
found a linear decrease in the response to asthma medica-
tions with increased BMI in atopic subjects. This decrease
did not occur in non-atopic patients. The potential
explanation for such finding is unclear and may relate tothe type of mechanisms on which medications act and how
they are altered by obesity.
One of the limitations of this study is the fact that it is a
retrospective analysis, although it provides important
information to guide future prospective studies. Further-
more, despite the smaller number of patients in this
analysis’s morbidly obese group, it is likely the most relevant
for the most obese members of the general population.
These observations should also be confirmed in more severe
asthma, as most of our subjects had mild to moderate
asthma.
In conclusion, the combination of an ICS and a LABA is
more likely to achieve asthma control than an ICS alone,
whatever patient weight. Furthermore, people who are both
obese and have asthma are less likely to achieve control
than their less-heavy counterparts. The causes of such
reduced response to asthma medication in obese subjects
should be studied and their implications for asthma therapy
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